​

​

• In type 1 diabetes, do glucagon-like peptide 1 analogs (GLP-1) improve patient-oriented
  outcomes. (Feb. 2021, UFA)

​

• In inadequately controlled type 1 diabetic patient, do the benefits of SGLT2
  /dual SGLT2/SGLT1 inhibitors seem to outweigh the risks. (April 2021, UFA)

​

• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (Fall
  Seminar May 2021, UFA)

​

• Collaborated as a key member of a clinical team during prelaunch activities of
  (Tresiba®, Victoza®, Ryzodeg® & Saxenda®) (2012-2018 Novo Nordisk – UAE)

​​

​​